These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 15316058)

  • 21. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
    Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
    Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic activation of the ret protooncogene in thyroid cancer.
    Takahashi M
    Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma.
    Jimenez C; Dang GT; Schultz PN; El-Naggar A; Shapiro S; Barnes EA; Evans DB; Vassilopoulou-Sellin R; Gagel RF; Cote GJ; Hoff AO
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3521-6. PubMed ID: 15240641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
    Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
    Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
    Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
    Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
    Ezzat S; Huang P; Dackiw A; Asa SL
    Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
    Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K; Okinaga H; Takami H
    Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells.
    Carson-Walter EB; Smith DP; Ponder BA; Baylin SB; Nelkin BD
    Oncogene; 1998 Jul; 17(3):367-76. PubMed ID: 9690518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
    Chiariello M; Visconti R; Carlomagno F; Melillo RM; Bucci C; de Franciscis V; Fox GM; Jing S; Coso OA; Gutkind JS; Fusco A; Santoro M
    Oncogene; 1998 May; 16(19):2435-45. PubMed ID: 9627110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoids differentially inhibit expression of the RET proto-oncogene.
    Capes-Davis A; Andrew SD; Hyland VJ; Twigg S; Learoyd DL; Dwight T; Marsh DJ; Robinson BG
    Gene Expr; 1999; 8(5-6):311-26. PubMed ID: 10947080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
    Maeda K; Murakami H; Yoshida R; Ichihara M; Abe A; Hirai M; Murohara T; Takahashi M
    Biochem Biophys Res Commun; 2004 Oct; 323(1):345-54. PubMed ID: 15351743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas.
    Shin E; Hong SW; Kim SH; Yang WI
    Yonsei Med J; 2004 Apr; 45(2):306-13. PubMed ID: 15119004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.